What Makes the Synthetic Control Design of ARASEC InnovativeByNeal Shore, MD, FACS,Rana R. McKay, MDJune 4th 2026
Comparing Perioperative Strategies in Cisplatin-Eligible MIBCByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MDJune 3rd 2026
Perioperative Therapy Expansion in Cisplatin-Ineligible MIBCByMax Kates, MD,Roger Li, MD,Abhinav Khanna, MDJune 3rd 2026
How a Post-RP MMAI Model Performed in a Long-Term Survivor PopulationByR. Jeffrey Karnes, MDJune 3rd 2026
Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate CancerByJason Hafron, MD,Ashley E. Ross, MD, PhD,Neeraj Agarwal, MD, FASCOJune 1st 2026